Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients

被引：26
|
作者：
Taniyama, M
Ohbayashi, S
Narita, M
Nakazawa, R
Hasegawa, S
Azuma, N
Teraoka, S
Ota, K
Yamauchi, S
Margolin, SB
机构：
[1] NARITA MEM HOSP, DEPT INTERNAL MED, TOYOHASHI, AICHI 441, JAPAN
[2] TOKATSU CLIN HOSP, DEPT NEPHROL, MATSUDO, CHIBA 271, JAPAN
[3] TOKYO WOMENS MED COLL, DEPT SURG, KIDNEY CTR, SHINJUKU KU, TOKYO 162, JAPAN
[4] KDL INC, CHIYODA KU, TOKYO, JAPAN
[5] MARNAC INC, DALLAS, TX 75225 USA
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1997年 / 52卷 / 01期
关键词：
pirfenidone; peritoneal sclerosis; haemodialysis;
D O I：
10.1007/s002280050252
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：77 / 78
页数：2
相关论文
共 50 条
  • [41] Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes
    Talpan, Delia
    Salla, Sabine
    Seidelmann, Nina
    Walter, Peter
    Fuest, Matthias
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [42] Novel pirfenidone analogs as antifibrotic agents: Synthesis and antifibrotic evaluation of 2-pyridones and fused pyridones
    Ismail, Magda M. F.
    Noaman, Eman
    MEDICINAL CHEMISTRY RESEARCH, 2005, 14 (07) : 382 - 403
  • [43] Novel Pirfenidone Analogs as Antifibrotic Agents: Synthesis and Antifibrotic Evaluation of 2-Pyridones and Fused Pyridones
    Magda M. F. Ismail
    Eman Noaman
    Medicinal Chemistry Research, 2005, 14 : 382 - 403
  • [44] Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis
    Sandri, Ana M.
    Landersdorfer, Cornelia B.
    Jacob, Jovan
    Boniatti, Marcio M.
    Dalarosa, Micheline G.
    Falci, Diego R.
    Behle, Taina F.
    Saitovitch, David
    Wang, Jiping
    Forrest, Alan
    Nation, Roger L.
    Zavascki, Alexandre P.
    Li, Jian
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (03) : 674 - 677
  • [45] A NEW HAEMODIALYSIS CATHETER-LOCKING AGENT REDUCES INFECTIONS IN HAEMODIALYSIS PATIENTS
    Taylor, Caroline
    Cahill, John
    Gerrish, Martin
    Little, Jane
    JOURNAL OF RENAL CARE, 2008, 34 (03) : 116 - 120
  • [46] The Impact of Switching to a Second Antifibrotic Therapy on Outcomes in Patients With IPF in the Empire Registry Treated With Pirfenidone or Nintedanib
    Vasakova, M. K.
    Mogulkoc, N.
    Kramer, M.
    Doubkova, M.
    Plackova, M.
    Mueller, V.
    Studnicka, M. J.
    Zurkova, M.
    Lacina, L.
    Lewandowska, K.
    Bartos, V.
    Ovesna, P.
    Gregor, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [47] Pharmacokinetics of tenofovir in haemodialysis
    Izzedine, H
    Launay-Vacher, V
    Jullien, V
    Aymard, G
    Duvivier, C
    Deray, G
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (09) : 1931 - 1933
  • [48] Pharmacokinetics of Trastuzumab in Haemodialysis
    Gori, Stefania
    Foglietta, Jennifer
    Lunardi, Gianluigi
    Inno, Alessandro
    Cardinali, Barbara
    Millo, Enrico
    Del Mastro, Lucia
    Nunzi, Emidio Giovanni
    Crino, Lucio
    Breast Journal, 2015, 21 (03): : 329 - 331
  • [49] Pharmacokinetics of bevacizumab in haemodialysis
    Garnier-Viougeat, Nathalie
    Rixe, Olivier
    Paintaud, Gilles
    Ternant, David
    Degenne, Danielle
    Mouawad, Roger
    Deray, Gilbert
    Izzedine, Hassane
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (03) : 975 - 975
  • [50] Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone - Results of a prospective, open-label phase II study
    Raghu, G
    Johnson, WC
    Lockhart, D
    Mageto, Y
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) : 1061 - 1069
12345